|Brand name(s), other common name(s)||Tasigna®|
|Drug type||Tyrosine kinase inhibitor|
|How the drug is given||By mouth|
Nilotinib is FDA approved to treat people who have Philadelphia-chromosome-positive chronic myeloid leukemia in adult patients whose disease could not be treated successfully with other therapies including imatinib (Gleevec®) or who cannot take imatinib.
Side effects needing medical attention:Irregularity in heartbeat; fainting; unexplained bleeding or bruising; blood in urine or stool; unexplained weakness; yellow skin and eyes; shortness of breath; swelling of hands, ankles, feet, or face; sudden stomach area pain with nausea and vomiting; low blood count; rash; nausea; headache; itching; tiredness; diarrhea; constipation.